Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

THERMO FISHER SCIENTIFIC

(TMO)
  Report
Real-time Estimate Cboe BZX  -  03:01 2022-12-06 pm EST
549.14 USD   -1.45%
08:01aThermo Fisher Scientific Raises Greenhouse Gas Emissions Reduction Target on Path to Net-zero Emissions
BU
11/29Transcript : Thermo Fisher Scientific Inc. Presents at 5th Annual Evercore ISI HealthCONx Conference 2022, Nov-29-2022 10:30 AM
CI
11/29Barclays Cuts Price Target on Thermo Fisher to $570 From $575, Maintains Overweight Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Thermo Fisher Scientific : Invests $160 Million to Expand Bioproduction Capacity in Greater Boston

09/20/2022 | 06:10am EST

New facility adds supply assurance and capacity to enable more life-saving vaccines and therapies

WALTHAM, Mass., September 20, 2022 - Thermo Fisher Scientific Inc., the world leader in serving science, today opened a new biomanufacturing facility in Chelmsford, Massachusetts. The $160 million, 85,000-square-foot facility will help meet growing demand for the biologic materials needed to produce vaccines and breakthrough therapies for cancer and other diseases. This new site is part of Thermo Fisher's $650 million multi-year investment to expand its bioprocessing production capabilities.

The technologies produced at the Chelmsford site are used in the purification process of developing biotherapeutics and vaccines. These products help save time and reduce costs so that new treatments can reach more patients faster. With the opening of the site in Chelmsford, Thermo Fisher continues to bring its capacity investments online to support customers as they grow and scale.

"This market continues to grow and the world's leading biopharmaceutical companies depend on our technologies, services and expertise to help deliver life changing therapies to patients," said Jean Luo, vice president and general manager, purification and pharma analytics, Thermo Fisher Scientific. "The Chelmsford site will help us provide our customers with the critical resin materials they need as they scale up production and bring new innovations to market. This ultimately helps ensure more patients get the treatments they need faster."

When fully staffed, the Chelmsford site will employ up to 250 people in roles across manufacturing, engineering, procurement, quality, warehousing, site leadership and more. This site is part of Thermo Fisher's global bioprocessing supply network that spans across 100 countries and helps ensure critical medicines reach patients. The Thermo Fisher network of sites have enabled more than 12 billion COVID-19 vaccine doses and partnered with customers to supply technology and materials for many currently approved COVID vaccines and therapeutics. Thermo Fisher employs more than 3,500 people in Massachusetts and operates over 15 facilities across the Commonwealth, including its corporate headquarters located in Waltham.

More information about Thermo Fisher's products and services can be found at thermofisher.com.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Disclaimer

Thermo Fisher Scientific Inc. published this content on 20 September 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 September 2022 10:09:23 UTC.


ę Publicnow 2022
All news about THERMO FISHER SCIENTIFIC
08:01aThermo Fisher Scientific Raises Greenhouse Gas Emissions Reduction Target on Path to Ne..
BU
11/29Transcript : Thermo Fisher Scientific Inc. Presents at 5th Annual Evercore IS..
CI
11/29Barclays Cuts Price Target on Thermo Fisher to $570 From $575, Maintains Overweight Rat..
MT
11/21Thermo Fisher Scientific Issues 1.25 Billion Euros of 2026, 2034 Notes
MT
11/21Thermo Fisher Scientific Inc. : Entry into a Material Definitive Agreement, Other Events, ..
AQ
11/21Thermo Fisher Scientific to Present at Evercore ISI HealthCONx Conference
BU
11/18Insider Sell: Thermo Fisher Scientific
MT
11/16Thermo Fisher Scientific : Introduces Rapid Point-of-Care RT-PCR Flu A/Flu B Test
PU
11/16Thermo Fisher Scientific to Seek Acquisitions
CI
11/16Thermo Fisher Scientific Introduces All-In-One AAV Production System for Scalable Gene ..
CI
More news
Analyst Recommendations on THERMO FISHER SCIENTIFIC
More recommendations
Financials (USD)
Sales 2022 43 857 M - -
Net income 2022 6 919 M - -
Net Debt 2022 24 995 M - -
P/E ratio 2022 31,8x
Yield 2022 0,21%
Capitalization 220 B 220 B -
EV / Sales 2022 5,58x
EV / Sales 2023 5,47x
Nbr of Employees 130 000
Free-Float 88,9%
Chart THERMO FISHER SCIENTIFIC
Duration : Period :
Thermo Fisher Scientific Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THERMO FISHER SCIENTIFIC
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 24
Last Close Price 557,21 $
Average target price 615,69 $
Spread / Average Target 10,5%
EPS Revisions
Managers and Directors
Marc N. Casper Chairman, President & Chief Executive Officer
Stephen Williamson Chief Financial Officer & Senior Vice President
Ryan Snyder Chief Information Officer & Senior Vice President
Alan B. Sachs Chief Medical Officer
Karen E. Nelson Chief Scientific Officer
Sector and Competitors